REGENXBIO Statistics
Total Valuation
REGENXBIO has a market cap or net worth of $432.95 million. The enterprise value is $264.36 million.
Important Dates
The next confirmed earnings date is Wednesday, November 6, 2024, after market close.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
REGENXBIO has 49.42 million shares outstanding. The number of shares has increased by 6.20% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 49.42M |
| Shares Change (YoY) | +6.20% |
| Shares Change (QoQ) | +10.64% |
| Owned by Insiders (%) | 7.60% |
| Owned by Institutions (%) | 79.80% |
| Float | 40.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.53 |
| Forward PS | 1.82 |
| PB Ratio | 1.24 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.97 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.53, with a Debt / Equity ratio of 0.46.
| Current Ratio | 3.53 |
| Quick Ratio | 3.41 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -44.92 |
Financial Efficiency
Return on equity (ROE) is -63.94% and return on invested capital (ROIC) is -27.10%.
| Return on Equity (ROE) | -63.94% |
| Return on Assets (ROA) | -24.26% |
| Return on Capital (ROIC) | -27.10% |
| Revenue Per Employee | $258,849 |
| Profits Per Employee | -$700,802 |
| Employee Count | 344 |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -152,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.86% in the last 52 weeks. The beta is 1.23, so REGENXBIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.23 |
| 52-Week Price Change | -42.86% |
| 50-Day Moving Average | 10.72 |
| 200-Day Moving Average | 14.44 |
| Relative Strength Index (RSI) | 34.98 |
| Average Volume (20 Days) | 450,932 |
Short Selling Information
The latest short interest is 4.99 million, so 10.09% of the outstanding shares have been sold short.
| Short Interest | 4.99M |
| Short Previous Month | 5.31M |
| Short % of Shares Out | 10.09% |
| Short % of Float | 12.23% |
| Short Ratio (days to cover) | 8.24 |
Income Statement
In the last 12 months, REGENXBIO had revenue of $89.04 million and -$241.08 million in losses. Loss per share was -$5.23.
| Revenue | 89.04M |
| Gross Profit | -176.76M |
| Operating Income | -242.96M |
| Pretax Income | -241.23M |
| Net Income | -241.08M |
| EBITDA | -226.02M |
| EBIT | -242.96M |
| Loss Per Share | -$5.23 |
Full Income StatementBalance Sheet
The company has $290.36 million in cash and $158.72 million in debt, giving a net cash position of $168.59 million or $3.41 per share.
| Cash & Cash Equivalents | 290.36M |
| Total Debt | 158.72M |
| Net Cash | 168.59M |
| Net Cash Per Share | $3.41 |
| Equity (Book Value) | 348.27M |
| Book Value Per Share | 7.06 |
| Working Capital | 248.41M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$191.12 million and capital expenditures -$3.60 million, giving a free cash flow of -$194.72 million.
| Operating Cash Flow | -191.12M |
| Capital Expenditures | -3.60M |
| Free Cash Flow | -194.72M |
| FCF Per Share | -$3.94 |
Full Cash Flow StatementMargins
Gross margin is -198.51%, with operating and profit margins of -272.86% and -270.74%.
| Gross Margin | -198.51% |
| Operating Margin | -272.86% |
| Pretax Margin | -270.91% |
| Profit Margin | -270.74% |
| EBITDA Margin | -253.83% |
| EBIT Margin | -272.86% |
| FCF Margin | -218.67% |
Dividends & Yields
REGENXBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.20% |
| Shareholder Yield | -6.20% |
| Earnings Yield | -55.68% |
| FCF Yield | -44.97% |
Analyst Forecast
The average price target for REGENXBIO is $37.70, which is 330.37% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $37.70 |
| Price Target Difference | 330.37% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 45.69% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REGENXBIO has an Altman Z-Score of -0.61 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.61 |
| Piotroski F-Score | 4 |